EA038798B1 - Анти-b7h3 антитела и связанные соединения и применение - Google Patents

Info

Publication number

EA038798B1

EA038798B1 EA201790465A EA201790465A EA038798B1 EA 038798 B1 EA038798 B1 EA 038798B1 EA 201790465 A EA201790465 A EA 201790465A EA 201790465 A EA201790465 A EA 201790465A EA 038798 B1 EA038798 B1 EA 038798B1

Authority

EA

Eurasian Patent Office

Prior art keywords

seq

antibody

antigen

binding

binding fragment

Prior art date

2014-08-27

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title description 15
• 230000027455 binding Effects 0.000 claims abstract description 209
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 142
• 108091007433 antigens Proteins 0.000 claims abstract description 125
• 102000036639 antigens Human genes 0.000 claims abstract description 125
• 239000000427 antigen Substances 0.000 claims abstract description 124
• 210000004027 cell Anatomy 0.000 claims abstract description 123
• 239000012634 fragment Substances 0.000 claims abstract description 105
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims abstract description 93
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 93
• 102100038078 CD276 antigen Human genes 0.000 claims abstract description 88
• 238000000034 method Methods 0.000 claims abstract description 88
• 201000011510 cancer Diseases 0.000 claims abstract description 71
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 67
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 43
• 210000004881 tumor cell Anatomy 0.000 claims abstract description 28
• 210000000987 immune system Anatomy 0.000 claims abstract description 14
• 230000002708 enhancing effect Effects 0.000 claims abstract description 6
• 239000003795 chemical substances by application Substances 0.000 claims description 225
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 217
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 197
• 229920001184 polypeptide Polymers 0.000 claims description 191
• 241000282414 Homo sapiens Species 0.000 claims description 59
• 230000000694 effects Effects 0.000 claims description 48
• 206010029260 Neuroblastoma Diseases 0.000 claims description 35
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 35
• 239000003814 drug Substances 0.000 claims description 35
• 239000000203 mixture Substances 0.000 claims description 29
• 229940124597 therapeutic agent Drugs 0.000 claims description 28
• 230000001225 therapeutic effect Effects 0.000 claims description 23
• 210000000822 natural killer cell Anatomy 0.000 claims description 22
• 230000014509 gene expression Effects 0.000 claims description 18
• 230000002401 inhibitory effect Effects 0.000 claims description 17
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
• 230000009870 specific binding Effects 0.000 claims description 14
• 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
• 230000003013 cytotoxicity Effects 0.000 claims description 11
• 231100000135 cytotoxicity Toxicity 0.000 claims description 11
• 230000003915 cell function Effects 0.000 claims description 7
• 229940079593 drug Drugs 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 238000011363 radioimmunotherapy Methods 0.000 claims description 7
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 6
• 238000001514 detection method Methods 0.000 claims description 6
• 239000000032 diagnostic agent Substances 0.000 claims description 6
• 230000002637 immunotoxin Effects 0.000 claims description 6
• 239000002596 immunotoxin Substances 0.000 claims description 6
• 229940051026 immunotoxin Drugs 0.000 claims description 6
• 231100000608 immunotoxin Toxicity 0.000 claims description 6
• 241000282553 Macaca Species 0.000 claims description 5
• 208000025174 PANDAS Diseases 0.000 claims description 5
• 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims description 5
• 235000016496 Panda oleosa Nutrition 0.000 claims description 5
• 241000282405 Pongo abelii Species 0.000 claims description 5
• 241000282898 Sus scrofa Species 0.000 claims description 5
• 241000700605 Viruses Species 0.000 claims description 5
• 210000002865 immune cell Anatomy 0.000 claims description 5
• 241001515942 marmosets Species 0.000 claims description 5
• 230000035755 proliferation Effects 0.000 claims description 5
• 238000010361 transduction Methods 0.000 claims description 5
• 230000026683 transduction Effects 0.000 claims description 5
• 238000001890 transfection Methods 0.000 claims description 5
• 241000283073 Equus caballus Species 0.000 claims description 4
• 241000282326 Felis catus Species 0.000 claims description 4
• 241000282620 Hylobates sp. Species 0.000 claims description 4
• 241000406668 Loxodonta cyclotis Species 0.000 claims description 4
• 241000282577 Pan troglodytes Species 0.000 claims description 4
• 239000012216 imaging agent Substances 0.000 claims description 4
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
• 240000004718 Panda Species 0.000 claims description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
• 201000010881 cervical cancer Diseases 0.000 claims description 3
• 229940039227 diagnostic agent Drugs 0.000 claims description 3
• 239000002105 nanoparticle Substances 0.000 claims description 3
• 241000009328 Perro Species 0.000 claims 2
• 230000010782 T cell mediated cytotoxicity Effects 0.000 abstract description 9
• 235000001014 amino acid Nutrition 0.000 description 89
• 229940024606 amino acid Drugs 0.000 description 86
• 150000001413 amino acids Chemical class 0.000 description 86
• 150000007523 nucleic acids Chemical class 0.000 description 68
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 66
• 102000039446 nucleic acids Human genes 0.000 description 64
• 108020004707 nucleic acids Proteins 0.000 description 64
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 55
• 235000018102 proteins Nutrition 0.000 description 55
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 53
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 53
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 43
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 43
• 239000000126 substance Substances 0.000 description 42
• 238000011282 treatment Methods 0.000 description 38
• 108060003951 Immunoglobulin Proteins 0.000 description 37
• 102000018358 immunoglobulin Human genes 0.000 description 37
• 230000035772 mutation Effects 0.000 description 35
• 229920000642 polymer Polymers 0.000 description 35
• 201000010099 disease Diseases 0.000 description 30
• 230000007935 neutral effect Effects 0.000 description 30
• 241001465754 Metazoa Species 0.000 description 27
• 230000000875 corresponding effect Effects 0.000 description 27
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 26
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 26
• 239000011230 binding agent Substances 0.000 description 26
• 208000035475 disorder Diseases 0.000 description 25
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
• 241000699666 Mus <mouse, genus> Species 0.000 description 22
• 125000003275 alpha amino acid group Chemical group 0.000 description 22
• 230000006870 function Effects 0.000 description 21
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 20
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 19
• 210000003169 central nervous system Anatomy 0.000 description 18
• 230000003993 interaction Effects 0.000 description 18
• 125000003729 nucleotide group Chemical group 0.000 description 18
• 108020004414 DNA Proteins 0.000 description 16
• 239000008280 blood Substances 0.000 description 16
• 230000001965 increasing effect Effects 0.000 description 16
• 210000004369 blood Anatomy 0.000 description 15
• 239000002773 nucleotide Substances 0.000 description 15
• 241001529936 Murinae Species 0.000 description 14
• 230000006052 T cell proliferation Effects 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 14
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 14
• 230000004071 biological effect Effects 0.000 description 14
• 238000006467 substitution reaction Methods 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• 238000011269 treatment regimen Methods 0.000 description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
• 210000004556 brain Anatomy 0.000 description 13
• 230000004044 response Effects 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 13
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 12
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 241000699670 Mus sp. Species 0.000 description 11
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
• 238000003752 polymerase chain reaction Methods 0.000 description 11
• 230000008685 targeting Effects 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• 239000013598 vector Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 210000005253 yeast cell Anatomy 0.000 description 11
• 206010025538 Malignant ascites Diseases 0.000 description 10
• 206010027476 Metastases Diseases 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 239000000872 buffer Substances 0.000 description 10
• 239000013078 crystal Substances 0.000 description 10
• 238000005516 engineering process Methods 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• -1 kshRNAs Proteins 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 239000013558 reference substance Substances 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 230000004083 survival effect Effects 0.000 description 10
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
• 239000004473 Threonine Substances 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 239000012636 effector Substances 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 150000002632 lipids Chemical class 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
• 230000009824 affinity maturation Effects 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 238000004422 calculation algorithm Methods 0.000 description 8
• 150000001720 carbohydrates Chemical class 0.000 description 8
• 235000014633 carbohydrates Nutrition 0.000 description 8
• 238000002648 combination therapy Methods 0.000 description 8
• UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 229920009537 polybutylene succinate adipate Polymers 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• 102220040657 rs199773433 Human genes 0.000 description 8
• 102200105532 rs397509387 Human genes 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 7
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 7
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 206010018338 Glioma Diseases 0.000 description 7
• 239000004471 Glycine Substances 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 7
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 7
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 239000013543 active substance Substances 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 238000009826 distribution Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 238000007912 intraperitoneal administration Methods 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 230000035800 maturation Effects 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 206010061289 metastatic neoplasm Diseases 0.000 description 7
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 102220004991 rs121912517 Human genes 0.000 description 7
• 102220288775 rs1554193610 Human genes 0.000 description 7
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
• 201000009030 Carcinoma Diseases 0.000 description 6
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 206010039491 Sarcoma Diseases 0.000 description 6
• 230000009286 beneficial effect Effects 0.000 description 6
• 229960002685 biotin Drugs 0.000 description 6
• 235000020958 biotin Nutrition 0.000 description 6
• 239000011616 biotin Substances 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 210000001218 blood-brain barrier Anatomy 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 231100000517 death Toxicity 0.000 description 6
• 230000000368 destabilizing effect Effects 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 238000000684 flow cytometry Methods 0.000 description 6
• 102000037865 fusion proteins Human genes 0.000 description 6
• 108020001507 fusion proteins Proteins 0.000 description 6
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
• 102000048770 human CD276 Human genes 0.000 description 6
• 230000002209 hydrophobic effect Effects 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 230000006872 improvement Effects 0.000 description 6
• 238000000126 in silico method Methods 0.000 description 6
• 238000002955 isolation Methods 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 230000009401 metastasis Effects 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 238000002600 positron emission tomography Methods 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 102200038304 rs61758405 Human genes 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
• 230000009885 systemic effect Effects 0.000 description 6
• 208000003174 Brain Neoplasms Diseases 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
• 150000008575 L-amino acids Chemical class 0.000 description 5
• 206010033128 Ovarian cancer Diseases 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 230000006287 biotinylation Effects 0.000 description 5
• 238000007413 biotinylation Methods 0.000 description 5
• 238000004364 calculation method Methods 0.000 description 5
• 125000003636 chemical group Chemical group 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 239000000562 conjugate Substances 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 238000010494 dissociation reaction Methods 0.000 description 5
• 230000005593 dissociations Effects 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 238000007913 intrathecal administration Methods 0.000 description 5
• 230000005291 magnetic effect Effects 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 230000000869 mutational effect Effects 0.000 description 5
• 230000002285 radioactive effect Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
• 229940045513 CTLA4 antagonist Drugs 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• 150000008574 D-amino acids Chemical class 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
• 102000048850 Neoplasm Genes Human genes 0.000 description 4
• 108700019961 Neoplasm Genes Proteins 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 241000288906 Primates Species 0.000 description 4
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• 108091008874 T cell receptors Proteins 0.000 description 4
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000003044 adaptive effect Effects 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 235000009582 asparagine Nutrition 0.000 description 4
• 229960001230 asparagine Drugs 0.000 description 4
• 235000003704 aspartic acid Nutrition 0.000 description 4
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
• 238000002659 cell therapy Methods 0.000 description 4
• 239000011651 chromium Substances 0.000 description 4
• 230000009089 cytolysis Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 210000004443 dendritic cell Anatomy 0.000 description 4
• 239000012091 fetal bovine serum Substances 0.000 description 4
• 150000004676 glycans Chemical class 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• 230000001506 immunosuppresive effect Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
• 229960000310 isoleucine Drugs 0.000 description 4
• 210000003292 kidney cell Anatomy 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 238000003032 molecular docking Methods 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 238000002703 mutagenesis Methods 0.000 description 4
• 231100000350 mutagenesis Toxicity 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 210000004303 peritoneum Anatomy 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000004088 simulation Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000011285 therapeutic regimen Methods 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 3
• 108010032595 Antibody Binding Sites Proteins 0.000 description 3
• 108091023037 Aptamer Proteins 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 102100029382 CMRF35-like molecule 6 Human genes 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• 206010051696 Metastases to meninges Diseases 0.000 description 3
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 239000007853 buffer solution Substances 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 208000019065 cervical carcinoma Diseases 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 150000005829 chemical entities Chemical class 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 238000004590 computer program Methods 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000001934 delay Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000004980 dosimetry Methods 0.000 description 3
• 238000012407 engineering method Methods 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 208000005017 glioblastoma Diseases 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000007914 intraventricular administration Methods 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 229960005386 ipilimumab Drugs 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000008297 liquid dosage form Substances 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 231100000682 maximum tolerated dose Toxicity 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 150000002739 metals Chemical class 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000002777 nucleoside Substances 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 230000005298 paramagnetic effect Effects 0.000 description 3
• 229960003330 pentetic acid Drugs 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• 238000011533 pre-incubation Methods 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 238000002818 protein evolution Methods 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 238000002603 single-photon emission computed tomography Methods 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 101150065190 term gene Proteins 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
• VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
• 208000006678 Abdominal Neoplasms Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 206010019233 Headaches Diseases 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
• 101100247598 Hordeum vulgare RCAA gene Proteins 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108700012912 MYCN Proteins 0.000 description 2
• 101150022024 MYCN gene Proteins 0.000 description 2
• 206010051676 Metastases to peritoneum Diseases 0.000 description 2
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
• 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
• 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 240000000220 Panda oleosa Species 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 229920005654 Sephadex Polymers 0.000 description 2
• 239000012507 Sephadex™ Substances 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 231100000987 absorbed dose Toxicity 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 230000001919 adrenal effect Effects 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 239000003125 aqueous solvent Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 238000011717 athymic nude mouse Methods 0.000 description 2
• 238000002869 basic local alignment search tool Methods 0.000 description 2
• 238000003766 bioinformatics method Methods 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 229920001222 biopolymer Polymers 0.000 description 2
• 230000001851 biosynthetic effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• 238000010609 cell counting kit-8 assay Methods 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 238000007621 cluster analysis Methods 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000005421 electrostatic potential Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 238000002710 external beam radiation therapy Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 230000003259 immunoinhibitory effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 239000012678 infectious agent Substances 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 230000002601 intratumoral effect Effects 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 238000000302 molecular modelling Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 125000003835 nucleoside group Chemical group 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 208000010918 peritoneal neoplasm Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 238000009520 phase I clinical trial Methods 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 150000004713 phosphodiesters Chemical group 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 210000003240 portal vein Anatomy 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
• 238000006722 reduction reaction Methods 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229940056501 technetium 99m Drugs 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 238000000108 ultra-filtration Methods 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
• FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
• FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
• QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
• PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
• YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
• JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
• RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
• XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
• ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
• AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
• FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
• UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• BUZOGVVQWCXXDP-VPENINKCSA-N 8-oxo-dGTP Chemical compound O=C1NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 BUZOGVVQWCXXDP-VPENINKCSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• 206010058040 Abdominal sepsis Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108050001427 Avidin/streptavidin Proteins 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 241001260012 Bursa Species 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 101710185679 CD276 antigen Proteins 0.000 description 1
• 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
• 229910052692 Dysprosium Inorganic materials 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014418 Electrolyte imbalance Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 229910052691 Erbium Inorganic materials 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 108010008177 Fd immunoglobulins Proteins 0.000 description 1
• CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 102220574129 Heart- and neural crest derivatives-expressed protein 1_I106L_mutation Human genes 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
• 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 description 1
• 101000984206 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 6 Proteins 0.000 description 1
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
• 241000282596 Hylobatidae Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
• XEEYBQQBJWHFJM-AKLPVKDBSA-N Iron-59 Chemical compound [59Fe] XEEYBQQBJWHFJM-AKLPVKDBSA-N 0.000 description 1
• 102220517121 Jerky protein homolog-like_L70M_mutation Human genes 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 108010023244 Lactoperoxidase Proteins 0.000 description 1
• 102000045576 Lactoperoxidases Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• 102100025553 Leukocyte immunoglobulin-like receptor subfamily A member 6 Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010052315 Lymphatic obstruction Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 101001033003 Mus musculus Granzyme F Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• NXTVQNIVUKXOIL-UHFFFAOYSA-N N-chlorotoluene-p-sulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NCl)C=C1 NXTVQNIVUKXOIL-UHFFFAOYSA-N 0.000 description 1
• 230000006051 NK cell activation Effects 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
• AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 238000012879 PET imaging Methods 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091093037 Peptide nucleic acid Proteins 0.000 description 1
• OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 241000158500 Platanus racemosa Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
• 241000283080 Proboscidea <mammal> Species 0.000 description 1
• 102220484577 Protein NDNF_S43A_mutation Human genes 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 102220495689 Putative uncharacterized protein FLJ43944_R40A_mutation Human genes 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 108091008103 RNA aptamers Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000007660 Residual Neoplasm Diseases 0.000 description 1
• 208000008938 Rhabdoid tumor Diseases 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 206010039509 Scab Diseases 0.000 description 1
• 101710204410 Scaffold protein Proteins 0.000 description 1
• BUGBHKTXTAQXES-AHCXROLUSA-N Selenium-75 Chemical compound [75Se] BUGBHKTXTAQXES-AHCXROLUSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 239000005708 Sodium hypochlorite Substances 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 229910052771 Terbium Inorganic materials 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010045515 Undifferentiated sarcoma Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 238000005411 Van der Waals force Methods 0.000 description 1
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 239000000370 acceptor Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 150000008065 acid anhydrides Chemical class 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 229940125666 actinium-225 Drugs 0.000 description 1
• QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 238000013357 binding ELISA Methods 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000008238 biochemical pathway Effects 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 239000005082 bioluminescent agent Substances 0.000 description 1
• 150000001615 biotins Chemical class 0.000 description 1
• 108091006004 biotinylated proteins Proteins 0.000 description 1
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 102220364176 c.205T>A Human genes 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 150000004697 chelate complex Chemical class 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000005081 chemiluminescent agent Substances 0.000 description 1
• 238000011976 chest X-ray Methods 0.000 description 1
• VEXZGXHMUGYJMC-OUBTZVSYSA-N chlorane Chemical compound [36ClH] VEXZGXHMUGYJMC-OUBTZVSYSA-N 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
• 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
• GUTLYIVDDKVIGB-YPZZEJLDSA-N cobalt-57 Chemical compound [57Co] GUTLYIVDDKVIGB-YPZZEJLDSA-N 0.000 description 1
• GUTLYIVDDKVIGB-BJUDXGSMSA-N cobalt-58 Chemical compound [58Co] GUTLYIVDDKVIGB-BJUDXGSMSA-N 0.000 description 1
• 239000002642 cobra venom Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000005695 dehalogenation reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• RKGLUDFWIKNKMX-UHFFFAOYSA-L dilithium;sulfate;hydrate Chemical compound [Li+].[Li+].O.[O-]S([O-])(=O)=O RKGLUDFWIKNKMX-UHFFFAOYSA-L 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000013104 docking experiment Methods 0.000 description 1
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000009513 drug distribution Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 238000001839 endoscopy Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• OGPBJKLSAFTDLK-IGMARMGPSA-N europium-152 Chemical compound [152Eu] OGPBJKLSAFTDLK-IGMARMGPSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 231100000755 favorable toxicity profile Toxicity 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000005002 female reproductive tract Anatomy 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 210000001652 frontal lobe Anatomy 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 229940006110 gallium-67 Drugs 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 description 1
• 231100001156 grade 3 toxicity Toxicity 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 230000007236 host immunity Effects 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical compound [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229940057428 lactoperoxidase Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
• 238000002357 laparoscopic surgery Methods 0.000 description 1
• WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 1
• 239000010985 leather Substances 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000009593 lumbar puncture Methods 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 201000001037 lung lymphoma Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000005389 magnetism Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 201000011614 malignant glioma Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002082 metal nanoparticle Substances 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 201000004058 mixed glioma Diseases 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000000329 molecular dynamics simulation Methods 0.000 description 1
• 238000000324 molecular mechanic Methods 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000003098 myoblast Anatomy 0.000 description 1
• 239000002159 nanocrystal Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000001020 neural plate Anatomy 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 238000002727 particle therapy Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 229940097886 phosphorus 32 Drugs 0.000 description 1
• 230000010399 physical interaction Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 210000002975 pon Anatomy 0.000 description 1
• DTBMTXYWRJNBGK-UHFFFAOYSA-L potassium;sodium;phthalate Chemical compound [Na+].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O DTBMTXYWRJNBGK-UHFFFAOYSA-L 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 239000002096 quantum dot Substances 0.000 description 1
• 230000005810 radionecrosis Effects 0.000 description 1
• 229960005562 radium-223 Drugs 0.000 description 1
• HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 1
• HCWPIIXVSYCSAN-YPZZEJLDSA-N radium-224 Chemical compound [224Ra] HCWPIIXVSYCSAN-YPZZEJLDSA-N 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
• 102200006121 rs1060501260 Human genes 0.000 description 1
• 102220223279 rs1060502343 Human genes 0.000 description 1
• 102220220520 rs1060503090 Human genes 0.000 description 1
• 102220239558 rs1553750097 Human genes 0.000 description 1
• 102220317882 rs1553902342 Human genes 0.000 description 1
• 102220317648 rs1553902415 Human genes 0.000 description 1
• 102220309985 rs1554139870 Human genes 0.000 description 1
• 102200007335 rs1554292444 Human genes 0.000 description 1
• 102220328919 rs1555631387 Human genes 0.000 description 1
• 102200158804 rs35481866 Human genes 0.000 description 1
• 102200010908 rs386833631 Human genes 0.000 description 1
• RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 239000004065 semiconductor Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000011452 sequencing regimen Methods 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000000547 structure data Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
• 150000003505 terpenes Chemical group 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000155 toxicity by organ Toxicity 0.000 description 1
• 230000007675 toxicity by organ Effects 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000005186 women's health Effects 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• QCWXUUIWCKQGHC-YPZZEJLDSA-N zirconium-89 Chemical compound [89Zr] QCWXUUIWCKQGHC-YPZZEJLDSA-N 0.000 description 1